

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 9, 2023**

**SYNOLOGIC, INC.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-37566**  
(Commission File Number)

**26-1824804**  
(IRS Employer  
Identification No.)

**301 Binney St.**  
**Suite 402**  
**Cambridge, Massachusetts**  
(Address of Principal Executive Offices)

**02142**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (617) 401-9975**

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	SYBX	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## Item 2.02 Results of Operations and Financial Condition.

On November 9, 2023, Synlogic, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

## Item 9.01 Financial Statements and Exhibits.

*(d) Exhibits*

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press Release dated November 9, 2023.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL Document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 9, 2023

Synlogic, Inc.

By: /s/ Michael Jensen

Name: Michael Jensen

Title: Chief Financial Officer

---



## Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

- Underwritten public offering of \$21.0 million and earned \$2.5 million milestone payment from Roche collaboration extended cash runway into the first half of 2025 -
- Progress of the Synpheny-3 pivotal trial in phenylketonuria (PKU) supports enrollment completion in 2024, with top-line data in the first half of 2025 -
- Company received Fast Track Designation from the FDA for labafenogene marselecobac (SYNB1934) as a potential treatment for PKU -

**Cambridge, Mass. November 9, 2023** – Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

“This quarter brought us important progress on multiple fronts, including the closing of a significant financing which extended our cash runway into the first half of 2025,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. “We are pleased with our progress in Synpheny-3, our ongoing pivotal study in PKU, which is also expected to readout in the first half of 2025, and we are grateful to our investigators and their staff at our clinical trial sites, as well as the PKU community for their continued support and partnership as we execute this landmark trial.”

### Recent Business Highlights

- Closing of \$21.0 million underwritten public offering, extending the Company’s cash runway into the first half of 2025.
- Progress with Synpheny-3, the pivotal study of labafenogene marselecobac for PKU, with operations across the United States and Canada, with additional countries expected before year-end 2023 and in early 2024.
- Receipt of Fast Track Designation from the FDA for labafenogene marselecobac for the treatment of phenylketonuria.
- Publication of Synpheny-1 Phase 2 study results for the PKU program in the journal *Nature Metabolism*.
- Presentation of Synpheny-1 Phase 2 study results by lead investigator Dr. Jerry Vockley of the University of Pittsburgh at the 37th E.S.PKU Conference 2023.
- Granting of an important US Patent (US Pat. No. 11,766,463), specifically covering the mutant PAL enzyme expressed by labafenogene marselecobac and extending the patent term exclusivity for SYNB1934 to 2041.

- Earning of \$2.5 million milestone payment for the achievement of prespecified success criteria under the research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD).

#### **Anticipated Milestones for Synpheny-3 Pivotal Study in PKU**

- Data safety monitoring board review of initial subset of data in the first half of 2024, potentially supporting study expansion to include 12- to 18-year-olds.
- Completion of full study enrollment in the second half of 2024.
- Release of top-line data in the first half of 2025.

#### **Upcoming Scientific & Industry Presentations**

- Caroline Kurtz, Ph.D., Chief Development Officer at Synlogic, will present “*Development of labafenogene marselecobac (SYNB1934), an engineered probiotic designed for the treatment of phenylketonuria (PKU)*,” on Thursday, November 16th at the 20th Orphan Drugs & Rare Diseases Global Congress 2023 Americas, held in Boston on November 16<sup>th</sup> and 17<sup>th</sup>.
- David Lubkowitz, M.S., Head, Strain Engineering & Characterization and HCU Program Lead at Synlogic, will present “*Improvements of SYNB1353, an Engineered Bacteria for the Treatment of Homocystinuria Lead to Increased in Vitro and In Vivo Degradation of Methionine*,” at the International Conference on Microbiome Engineering 2023, held in Berkley, California on December 8<sup>th</sup> to 10<sup>th</sup>.

#### **Third Quarter 2023 Financial Results and Financial Outlook**

As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of \$33.4 million, not inclusive of the October financing of \$19.6 million (net), and an additional \$2.5 million earned from the Roche research collaboration announced in November.

Revenue for the three months ended September 30, 2023 was \$0.4 million compared to \$0.7 million for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease.

For the three months ended September 30, 2023, Synlogic reported a consolidated net loss of \$12.1 million, or \$2.57 per share, compared to a consolidated net loss of \$17.9 million, or \$3.73 per share, for the corresponding period in 2022.

Research and development expenses were \$9.6 million for the three months ended September 30, 2023, compared to \$14.6 million for the corresponding period in 2022.

General and administrative expenses were \$3.4 million for the three months ended September 30, 2023, compared to \$4.4 million for the corresponding period in 2022.

Based upon its current operating plan and inclusive of the net cash proceeds from the October financing and milestone payment from Roche, Synlogic expects to have sufficient cash to be able to fund operations further into the first half of 2025.

## **Investor Conference Participation**

Synlogic leadership will participate in The H.C. Wainwright Global Investment Conference, being held September 11-13, 2023 in-person in New York City. Participation will include both investor meetings and a company presentation. A live webcast of the presentation, if available, will be accessible under the "Event Calendar" in the Investors & Media section of the Synlogic website. An archived version will be available afterwards at the same location.

## **About Synlogic**

Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. The Company's late-stage pipeline is focused on rare metabolic diseases, led by labafenogene marselecobac (SYNB1934), currently being studied as a potential treatment for phenylketonuria (PKU) in Synpheny-3, a global, pivotal Phase 3 study. Additional product candidates address diseases including homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. This pipeline is fueled by the Synthetic Biotic platform, which applies precision genetic engineering to well-characterized probiotics. This enables Synlogic to create GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for PKU and HCU, both inborn errors of metabolism, as well as other disorders in which the disease-specific metabolites transit through the GI tract, providing validated targets for these Synthetic Biotics. Research activities include a partnership with Roche focused on inflammatory bowel disease (IBD), and a collaboration with Ginkgo Bioworks in synthetic biology, which has contributed to two pipeline programs to date. For more information, please visit [www.synlogictx.com](http://www.synlogictx.com) or follow us on Twitter, LinkedIn, Facebook or Instagram.

## **Forward Looking Statements**

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "look forward," "estimate," "expect," "focused on," "intend," "on track," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are

not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of labafenogene marselecoabac (previously known as SYN1934), SYN1353, SYN8802 and SYN2081 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

----

**Media Contact:** [media@synlogictx.com](mailto:media@synlogictx.com)

**Investor Relations:** [investor@synlogictx.com](mailto:investor@synlogictx.com)

**Synlogic, Inc.**  
**Condensed Consolidated Statements of Operations**  
(unaudited)

(in thousands except share and per share data)

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2023	2022	2023	2022
Revenue	\$ 393	\$ 678	\$ 602	\$ 1,074
Operating expenses				
Research and development	9,616	14,610	33,831	38,405
General and administrative	3,400	4,402	11,291	12,785
Total operating expenses	<u>13,016</u>	<u>19,012</u>	<u>45,122</u>	<u>51,190</u>
Loss from operations	(12,623)	(18,334)	(44,520)	(50,116)
Other income, net	548	422	1,784	665
Loss before income taxes	(12,075)	(17,912)	(42,736)	(49,451)
Income tax expense	(3)	-	(12)	-
Net loss	<u>\$ (12,078)</u>	<u>\$ (17,912)</u>	<u>\$ (42,748)</u>	<u>\$ (49,451)</u>
Net loss per share - basic and diluted	<u>\$ (2.57)</u>	<u>\$ (3.73)</u>	<u>\$ (9.17)</u>	<u>\$ (10.29)</u>
Weighted-average common shares used in computing net loss per share - basic and diluted	<u>4,699,847</u>	<u>4,807,207</u>	<u>4,662,444</u>	<u>4,804,127</u>

**Synlogic, Inc.**  
**Condensed Consolidated Balance Sheets**  
(unaudited)

(in thousands, except share data)

	<b>September 30, 2023</b>	<b>December 31, 2022</b>
<b>Assets</b>		
Cash, cash equivalents, & marketable securities	\$ 33,415	\$ 77,629
Property and equipment, net	5,949	7,323
Other assets	26,890	25,913
<b>Total assets</b>	<b>\$ 66,254</b>	<b>\$ 110,865</b>
<b>Liabilities and stockholders' equity</b>		
Current liabilities	\$ 9,144	\$ 12,122
Long-term liabilities	13,706	16,133
<b>Total liabilities</b>	<b>22,850</b>	<b>28,255</b>
Total stockholders' equity	43,404	82,610
<b>Total liabilities and stockholders' equity</b>	<b>\$ 66,254</b>	<b>\$ 110,865</b>
Common stock and common stock equivalents		
Common stock	4,598,297	4,449,082
Common stock warrants (pre-funded)	169,874	169,874
<b>Total common stock</b>	<b>4,768,171</b>	<b>4,618,956</b>

